-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the Guangdong Pharmaceutical Association released the latest version of the "Catalog of Drugs Used in Exceeding Instructions (2021 Edition)"
.
"Medication beyond the drug insert" refers to the medication plan that exceeds the contents of the drug insert, including the indications for the use of the drug, the applicable population, the method of administration, or the usage where the dosage is not within the insert approved by the domestic drug regulatory authority
.
Standard off-label drugs have positive clinical value, and they can give patients therapeutic benefits by playing the cutting-edge therapeutic effects of drugs
.
This article collates the relevant content of the newly released "Extra Drug Insert Medication List" for urinary tumors for your reference
.
Bevacizumab indications: metastatic renal cell carcinoma (combined with interferon).
Specific usage: combined with interferon.
Bevacizumab is recommended for intravenous infusion of 10mg/kg, once every two weeks
.
Micromedex classification: Effectiveness Class Ⅱa, Recommendation Class Ⅱb, Strength of evidence Category B Gemcitabine Indications: Bladder cancer Specific usage: Refer to guidelines and references: 1.
The US FDA has not approved gemcitabine for the treatment of bladder cancer.
2.
NCCN clinical practice Guideline: Bladder Cancer 2021.
V23.
Hematology Oncology Committee of Chinese Anti-Cancer Association, "Bladder Cancer Diagnosis and Treatment Standards" (2018 Edition) micromedex classification: Effectiveness Class Ⅱa, Recommendation Class Ⅱb, Evidence Strength Category B Nivolumab adaptation Syndrome: Intermediate to high-risk advanced renal cell carcinoma (combined with ipilimumab or monotherapy for patients who have received anti-angiogenesis therapy) Specific usage: combined with ipilimumab: intravenous infusion of 3 mg·kg-1 within 30 minutes , And then give Ipilimumab 1 mg·kg-1 on the same day, 4 doses every 3 weeks
.
Then every 2 weeks or every 4 weeks, 240 mg or 480 mg of Micromedex is given by intravenous infusion.
Classification: Effectiveness Class I (combined with Ipilimumab), Class IIa (single agent), recommendation Class Ⅱa, evidence strength Category B Pembrolizumab Indications: First-line treatment of advanced renal cell carcinoma with axitinib.
Specific usage: 200mg, intravenous infusion for more than 30 minutes, repeated every 3 weeks or 400mg, intravenous infusion for more than 30 minutes, repeated every 6 weeks, combined with axitinib5 mg, twice daily for 24 months, or until disease progression or unacceptable toxicity.
Micromedex classification: Effectiveness Class I, Recommended Class Ⅱa, Evidence Strength Category B Indications: Locally advanced or metastatic urothelium Specific usage of cell cancer: 200 mg intravenously every 3 weeks for more than 30 minutes, or 400 mg intravenously for more than 30 minutes every 6 weeks for 24 months, or until unacceptable toxicity or disease progression occurs.
Micromedex classification: Effectiveness Class I, recommended Class I, Evidence Strength Category B Source: Guangdong Pharmaceutical Association official website
.
"Medication beyond the drug insert" refers to the medication plan that exceeds the contents of the drug insert, including the indications for the use of the drug, the applicable population, the method of administration, or the usage where the dosage is not within the insert approved by the domestic drug regulatory authority
.
Standard off-label drugs have positive clinical value, and they can give patients therapeutic benefits by playing the cutting-edge therapeutic effects of drugs
.
This article collates the relevant content of the newly released "Extra Drug Insert Medication List" for urinary tumors for your reference
.
Bevacizumab indications: metastatic renal cell carcinoma (combined with interferon).
Specific usage: combined with interferon.
Bevacizumab is recommended for intravenous infusion of 10mg/kg, once every two weeks
.
Micromedex classification: Effectiveness Class Ⅱa, Recommendation Class Ⅱb, Strength of evidence Category B Gemcitabine Indications: Bladder cancer Specific usage: Refer to guidelines and references: 1.
The US FDA has not approved gemcitabine for the treatment of bladder cancer.
2.
NCCN clinical practice Guideline: Bladder Cancer 2021.
V23.
Hematology Oncology Committee of Chinese Anti-Cancer Association, "Bladder Cancer Diagnosis and Treatment Standards" (2018 Edition) micromedex classification: Effectiveness Class Ⅱa, Recommendation Class Ⅱb, Evidence Strength Category B Nivolumab adaptation Syndrome: Intermediate to high-risk advanced renal cell carcinoma (combined with ipilimumab or monotherapy for patients who have received anti-angiogenesis therapy) Specific usage: combined with ipilimumab: intravenous infusion of 3 mg·kg-1 within 30 minutes , And then give Ipilimumab 1 mg·kg-1 on the same day, 4 doses every 3 weeks
.
Then every 2 weeks or every 4 weeks, 240 mg or 480 mg of Micromedex is given by intravenous infusion.
Classification: Effectiveness Class I (combined with Ipilimumab), Class IIa (single agent), recommendation Class Ⅱa, evidence strength Category B Pembrolizumab Indications: First-line treatment of advanced renal cell carcinoma with axitinib.
Specific usage: 200mg, intravenous infusion for more than 30 minutes, repeated every 3 weeks or 400mg, intravenous infusion for more than 30 minutes, repeated every 6 weeks, combined with axitinib5 mg, twice daily for 24 months, or until disease progression or unacceptable toxicity.
Micromedex classification: Effectiveness Class I, Recommended Class Ⅱa, Evidence Strength Category B Indications: Locally advanced or metastatic urothelium Specific usage of cell cancer: 200 mg intravenously every 3 weeks for more than 30 minutes, or 400 mg intravenously for more than 30 minutes every 6 weeks for 24 months, or until unacceptable toxicity or disease progression occurs.
Micromedex classification: Effectiveness Class I, recommended Class I, Evidence Strength Category B Source: Guangdong Pharmaceutical Association official website
